Similar articles

Abstract: hepatocarcinoma is one of the malignant cancers with significant morbidity and mortality. immunotherapy has emerged in clinical treatment, owing to the limitation and severe side effects of chemotherapy. In the immune system, natural killer (NK) cells are important effectors required to eliminate malignant tumor cells without the limitation of major histocompatibility complex (MHC) molecule issues. Hence, treatment which could stimulate NK cells is of great interest. Here, we investigated the efficacy of the combined therapy of TT-1 (a mutant of melittin) and interferon-α; (IFN-α;) on NK cells and human liver cancer HepG-2/Huh7 cells in vitro and in vivo, as well as the mechanism involved. The combination therapy significantly inhibited the growth of HepG-2/Huh7 cells in vivo, but this effect was impaired after depleting NK cells. TT-1 not only up-regulated MHC class I-related chain molecules A (MICA) expression, but also prevented the secretion of soluble MICA (sMICA). Both the mRNA and protein of a disintegrin and metallopeptidase 10 (ADAM 10) in HepG-2/Huh7 cells were decreased after TT-1 treatment. The combined therapy of TT-1 and IFN-α could suppress the growth of HepG-2/Huh7 xenografted tumor effectively via promoting the interaction of NK group 2, member D (NKG2D) and MICA, indicating that TT-1+IFN-α would be a potential approach in treating liver cancer.

联合使用IFN-α和TT-1通过增强NKG2D和MICA的相互作用达到抗肝癌效果的研究

[1]Boige, V., Taïeb, J., Hebbar, M., et al., 2006. Irinotecan as first-line chemotherapy in patients with advanced hepatocellular carcinoma: a multicenter phase II study with dose adjustment according to baseline serum bilirubin level. Eur. J. Cancer, 42(4):456-459.

[2]Brown, C.K., Kirkwood, J.M., 2003. Medical management of melanoma. Surg. Clin. North Am., 83(2):283-322.

[3]Cerwenka, A., Baron, J.L., Lanier, L.L., 2001. Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo. Proc. Natl. Acad. Sci. USA, 98(20):11521-11526.

[4]Dusheiko, G.M., Hobbs, K.E., Dick, R., et al., 1992. Treatment of small hepatocellular carcinomas. Lancet, 340(8814): 285-288.

[5]Floros, T., Tarhini, A.A., 2015. Anticancer cytokines: biology and clinical effects of IFN-α2, IL-2, IL-15, IL-21, and IL-12. Semin. Oncol., 42(4):539-548.

[6]Groh, V., Wu, J., Yee, C., et al., 2002. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature, 419(6908):734-738.

[7]Guan, Z., Wang, Y., Maoleekoonpairoj, S., et al., 2003. Prospective randomized phase II study of gemcitabine at standard or fixed dose rate schedule in unresectable hepatocellular carcinoma. Br. J. Cancer, 89(10):1865-1869.

[8]Habu, S., Fukui, H., Shimamura, K., et al., 1981. In vivo effects of anti-asialo GM1. I. Reduction of NK activity and enhancement of transplanted tumor growth in nude mice. J. Immunol., 127(1):34-38.

[9]Hebbar, M., Ernst, O., Cattan, S., et al., 2006. Phase II trial of docetaxel therapy in patients with advanced hepatocellular carcinoma. Oncology, 70(2):154-158.

[10]Hung, H., 2005. Treatment modalities for hepatocellular carcinoma. Curr. Cancer Drug Targets, 5(2):131-138.

[11]Lee, W.P., Tai, D.I., Tsai, S.L., et al., 2003. Adenovirus type 5 E1A sensitizes hepatocellular carcinoma cells to gemcitabine. Cancer Res., 63(19):6229-6236.

[12]Leung, H.W., Yang, W.H., Lai, M.Y., et al., 2007. Inhibition of 12-lipoxygenase during baicalein-induced human lung non-small carcinoma H460 cell apoptosis. Food Chem. Toxicol., 45(3):403-411.

[13]Liu, Y., Yue, H., Xu, S., et al., 2015. First-line gemcitabine and oxaliplatin (GEMOX) plus sorafenib, followed by sorafenib as maintenance therapy, for patients with advanced hepatocellular carcinoma. Int. J. Clin. Oncol., 20(5):952-959.

[14]Liu, Y., Li, Y., Wang, R., et al., 2016. MiR-130a-3p regulates cell migration and invasion via inhibition of Smad4 in gemcitabine resistant hepatoma cells. J. Exp. Clin. Cancer Res., 35:19.

[15]Morisaki, T., Onishi, H., Koya, N., et al., 2011. Combinatorial cytotoxicity of gemcitabine and cytokine-activated killer cells in hepatocellular carcinoma via the NKG2D-MICA/B system. Anticancer Res., 31(7):2505-2510.

[16]Mundy-Bosse, B.L., Lesinski, G.B., Jaime-Ramirez, A.C., et al., 2011. Myeloid-derived suppressor cell inhibition of the IFN response in tumor-bearing mice. Cancer Res., 71(15):5101-5110.

[17]Oršolić, N., 2012. Bee venom in cancer therapy. Cancer Metastasis Rev., 31(1-2):173-194.

[18]Parlato, S., Santini, S.M., Lapenta, C., et al., 2001. Expression of CCR-7, MIP-3β, and Th-1 chemokines in type I IFN-induced monocyte-derived dendritic cells: importance for the rapid acquisition of potent migratory and functional activities. Blood, 98(10):3022-3029.

[19]Reiss, K., Ludwig, A., Saftig, P., 2006. Breaking up the tie: disintegrin-like metalloproteinases as regulators of cell migration in inflammation and invasion. Pharmacol. Ther., 111(3):985-1006.

[20]Salih, H.R., Rammensee, H.G., Steinle, A., 2002. Cutting edge: down-regulation of MICA on human tumors by proteolytic shedding. J. Immunol., 169(8):4098-4102.

[21]Sommer, A., Fries, A., Cornelsen, I., et al., 2012. Melittin modulates keratinocyte function through P2 receptor-dependent ADAM activation. J. Biol. Chem., 287(28): 23678-23689.

[22]Son, D.J., Lee, J.W., Lee, Y.H., et al., 2007. Therapeutic application of anti-arthritis, pain-releasing, and anticancer effects of bee venom and its constituent compounds. Pharmacol. Ther., 115(2):246-270.

[23]Taïeb, J., Bonyhay, L., Golli, L., et al., 2003. Gemcitabine plus oxaliplatin for patients with advanced hepatocellular carcinoma using two different schedules. Cancer, 98(12): 2664-2670.

[24]Thompson, C.B., Allison, J.P., 1997. The emerging role of CTLA-4 as an immune attenuator. Immunity, 7(4):445-450.

[25]Ueda, K., Akiba, J., Ogasawara, S., et al., 2016. Growth inhibitory effect of an injectable hyaluronic acid-tyramine hydrogels incorporating human natural interferon-α and sorafenib on renal cell carcinoma cells. Acta Biomater., 29:103-111.

[26]Waldhauer, I., Steinle, A., 2006. Proteolytic release of soluble UL16-binding protein 2 from tumor cells. Cancer Res., 66(5):2520-2526.

[27]Waldhauer, I., Goehlsdorf, D., Gieseke, F., et al., 2008. Tumor-associated MICA is shed by ADAM proteases. Cancer Res., 68(15):6368-6376.

[28]Wang, T., Sun, F., Xie, W., et al., 2016. A bispecific protein rG7S-MICA recruits natural killer cells and enhances NKG2D-mediated immunosurveillance against hepatocellular carcinoma. Cancer Lett., 372(2):166-178.

[29]Wu, J.D., Higgins, L.M., Steinle, A., et al., 2004. Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancer. J. Clin. Invest., 114(4):560-568.

[30]Wu, J.D., Atteridge, C.L., Wang, X., et al., 2009. Obstructing shedding of the immunostimulatory MHC class I chain-related gene B prevents tumor formation. Clin. Cancer Res., 15(2):632-640.

[31]Xie, W., Liu, F., Wang, Y., et al., 2016. VEGFR2 targeted antibody fused with MICA stimulates NKG2D mediated immunosurveillance and exhibits potent anti-tumor activity against breast cancer. Oncotarget, 7(13):16445-16461.

[32]Yang, J.T., Tang, L.H., Liu, Y.Q., et al., 2015. Cisplatin combined with hyperthermia kills HepG2 cells in intraoperative blood salvage but preserves the function of erythrocytes. J. Zhejiang Univ.-Sci. B (Biomed. & Biotechnol.), 16(5):395-403.

[33]Zwirner, N.W., Fuertes, M.B., Girart, M.V., et al., 2007. Cytokine-driven regulation of NK cell functions in tumor immunity: role of the MICA-NKG2D system. Cytokine Growth Factor Rev., 18(1-2):159-170.